These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35240229)

  • 1. Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study.
    Salemme A; Fania L; Scarabello A; Caproni M; Marzano AV; Cozzani E; Feliciani C; De Simone C; Papini M; Satta RR; Parodi A; Mariotti F; Lechiancole S; Genovese G; Passarelli F; Festa F; Bellei B; Provini A; Sordi D; Pallotta S; Abeni D; Mazzanti C; Didona B; Di Zenzo G;
    J Am Acad Dermatol; 2022 Jul; 87(1):56-63. PubMed ID: 35240229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
    Nätynki A; Leisti P; Tuusa J; Varpuluoma O; Huilaja L; Izumi K; Herukka SK; Ukkola O; Junttila J; Kokkonen N; Tasanen K
    Front Immunol; 2022; 13():942131. PubMed ID: 35958564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
    Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
    Front Immunol; 2018; 9():1030. PubMed ID: 29881377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
    García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
    Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
    Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
    Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
    Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
    J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
    Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
    J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis.
    Christophoridis S; Büdinger L; Borradori L; Hunziker T; Merk HF; Hertl M
    Br J Dermatol; 2000 Aug; 143(2):349-55. PubMed ID: 10951144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.
    Emtenani S; Yuan H; Lin C; Pan M; Hundt JE; Schmidt E; Komorowski L; Stanley JR; Hammers CM
    Br J Dermatol; 2019 May; 180(5):1099-1106. PubMed ID: 30315657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
    Feliciani C; Caldarola G; Kneisel A; Podstawa E; Pfütze M; Pfützner W; Hertl M
    Br J Dermatol; 2009 Aug; 161(2):306-12. PubMed ID: 19485996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
    Di Zenzo G; Thoma-Uszynski S; Fontao L; Calabresi V; Hofmann SC; Hellmark T; Sebbag N; Pedicelli C; Sera F; Lacour JP; Wieslander J; Bruckner-Tuderman L; Borradori L; Zambruno G; Hertl M
    Clin Immunol; 2008 Sep; 128(3):415-26. PubMed ID: 18571472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230.
    Thoma-Uszynski S; Uter W; Schwietzke S; Schuler G; Borradori L; Hertl M
    J Immunol; 2006 Feb; 176(3):2015-23. PubMed ID: 16424234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
    Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study.
    Dikmen HO; Yilmaz K; Benoit S; Bernard P; Drenovska K; Gerdes S; Gläser R; Günther C; Homey B; Horváth ON; Huilaja L; Joly P; Kiritsi D; Meller S; Patsatsi A; Sárdy M; Schauer F; Shahid M; Sticherling M; Tasanen K; Vassileva S; Worm M; Zillikens D; Sadik CD; van Beek N; König IR; Schmidt E
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2181-2189. PubMed ID: 35796163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
    Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
    Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.